Ian Alberts1, Christos Sachpekidis2, Eleni Gourni2, Silvan Boxler3, Tobias Gross3, George Thalmann3, Kambiz Rahbar4, Axel Rominger2, Ali Afshar-Oromieh2. 1. Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstr. 18, 3010, Bern, Switzerland. ian.alberts@insel.ch. 2. Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstr. 18, 3010, Bern, Switzerland. 3. Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 4. Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Abstract
PURPOSE: Dual-time point PET/CT scanning with [68Ga]Ga-PSMA-11 in the diagnosis of prostate cancer (PC) has been advanced as a method to increase detection of PC lesions, particularly at early stages of biochemical recurrence and as a potential means to aid the discrimination between benign and pathological prostate-specific membrane antigen (PSMA) uptake. However, the assumption that all PC lesions uniformly exhibit increasing tracer uptake at delayed imaging has not yet been investigated, which this present study aims to address. METHODS: One hundred consecutive patients with biochemically recurrent PC who received standard and late [68Ga]Ga-PSMA-11 PET/CT (by local protocol at 1.5 h "standard" and 2.5 h p.i. "late") underwent retrospective evaluation. All lesions with a tracer uptake above local background were analysed with regard to their maximum standardised uptake values at standard and late images (SUVmax) and characterised according to their morphological characteristics. RESULTS: Seventy-nine of 100 patients had PSMA-positive scans, in whom a total of 185 individual PSMA-positive lesions were identified. These were morphologically characterised as bone lesions (n = 48), solid organ lesions (n = 3), lymph node (LN) lesions (n = 78) and locally recurrent lesions in the prostatic fossa or seminal vesicles (n = 56). The relative uptake between standard and late imaging was considered; all lesions classified as local recurrence presented with increasing (86%) or stable patterns of tracer uptake (14%). In contrast, only 58% of bone lesions exhibited increasing tracer uptake, with 21% exhibiting a stable pattern and 21% exhibiting a decreasing tracer uptake at late imaging. CONCLUSION: A heterogeneous pattern of dynamic tracer uptake was observed, with a largely increasing pattern observed for locally recurrent lesions and lymph nodes and a significant proportion of bone lesions exhibiting decreasing tracer uptake. The results are of significance not only in the imaging and identification of PC lesions, but they also have implications for PSMA-directed ligand therapy.
PURPOSE: Dual-time point PET/CT scanning with [68Ga]Ga-PSMA-11 in the diagnosis of prostate cancer (PC) has been advanced as a method to increase detection of PC lesions, particularly at early stages of biochemical recurrence and as a potential means to aid the discrimination between benign and pathological prostate-specific membrane antigen (PSMA) uptake. However, the assumption that all PC lesions uniformly exhibit increasing tracer uptake at delayed imaging has not yet been investigated, which this present study aims to address. METHODS: One hundred consecutive patients with biochemically recurrent PC who received standard and late [68Ga]Ga-PSMA-11 PET/CT (by local protocol at 1.5 h "standard" and 2.5 h p.i. "late") underwent retrospective evaluation. All lesions with a tracer uptake above local background were analysed with regard to their maximum standardised uptake values at standard and late images (SUVmax) and characterised according to their morphological characteristics. RESULTS: Seventy-nine of 100 patients had PSMA-positive scans, in whom a total of 185 individual PSMA-positive lesions were identified. These were morphologically characterised as bone lesions (n = 48), solid organ lesions (n = 3), lymph node (LN) lesions (n = 78) and locally recurrent lesions in the prostatic fossa or seminal vesicles (n = 56). The relative uptake between standard and late imaging was considered; all lesions classified as local recurrence presented with increasing (86%) or stable patterns of tracer uptake (14%). In contrast, only 58% of bone lesions exhibited increasing tracer uptake, with 21% exhibiting a stable pattern and 21% exhibiting a decreasing tracer uptake at late imaging. CONCLUSION: A heterogeneous pattern of dynamic tracer uptake was observed, with a largely increasing pattern observed for locally recurrent lesions and lymph nodes and a significant proportion of bone lesions exhibiting decreasing tracer uptake. The results are of significance not only in the imaging and identification of PC lesions, but they also have implications for PSMA-directed ligand therapy.
Authors: Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2017-06 Impact factor: 9.236
Authors: Ali Afshar-Oromieh; Lars Peter Sattler; Walter Mier; Boris A Hadaschik; Jürgen Debus; Tim Holland-Letz; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2017-01-06 Impact factor: 10.057
Authors: Ali Afshar-Oromieh; Henrik Hetzheim; Clemens Kratochwil; Martina Benesova; Matthias Eder; Oliver C Neels; Michael Eisenhut; Wolfgang Kübler; Tim Holland-Letz; Frederik L Giesel; Walter Mier; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2015-08-20 Impact factor: 10.057
Authors: Christos Sachpekidis; Klaus Kopka; Matthias Eder; Boris A Hadaschik; Martin T Freitag; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss Journal: Clin Nucl Med Date: 2016-11 Impact factor: 7.794
Authors: Christoph Rischpler; Teresa I Beck; Shozo Okamoto; Anna M Schlitter; Karina Knorr; Markus Schwaiger; Jürgen Gschwend; Tobias Maurer; Philipp T Meyer; Matthias Eiber Journal: J Nucl Med Date: 2018-01-25 Impact factor: 10.057
Authors: Nicola Fossati; R Jeffrey Karnes; Michele Colicchia; Stephen A Boorjian; Alberto Bossi; Thomas Seisen; Nadia Di Muzio; Cesare Cozzarini; Barbara Noris Chiorda; Claudio Fiorino; Giorgio Gandaglia; Paolo Dell'Oglio; Shahrokh F Shariat; Gregor Goldner; Steven Joniau; Antonino Battaglia; Karin Haustermans; Gert De Meerleer; Valérie Fonteyne; Piet Ost; Hendrik Van Poppel; Thomas Wiegel; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2017-08-02 Impact factor: 20.096
Authors: Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-20 Impact factor: 9.236
Authors: Ian Alberts; Robin Schepers; Konstantinos Zeimpekis; Hasan Sari; Axel Rominger; Ali Afshar-Oromieh Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-22 Impact factor: 10.057
Authors: Ian Leigh Alberts; Svenja Elizabeth Seide; Clemens Mingels; Karl Peter Bohn; Kuangyu Shi; Helle D Zacho; Axel Rominger; Ali Afshar-Oromieh Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-06 Impact factor: 9.236
Authors: Janna Morawitz; Julian Kirchner; Johannes Hertelendy; Christina Loberg; Lars Schimmöller; Mardjan Dabir; Lena Häberle; Eduards Mamlins; Christina Antke; Christian Arsov; Gerald Antoch; Lino M Sawicki Journal: EJNMMI Res Date: 2022-03-04 Impact factor: 3.138
Authors: Falk Gühne; Stefanie Radke; Thomas Winkens; Christian Kühnel; Julia Greiser; Philipp Seifert; Robert Drescher; Martin Freesmeyer Journal: Pharmaceuticals (Basel) Date: 2021-12-22
Authors: Clemens Mingels; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh; Ian Alberts Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-24 Impact factor: 10.057
Authors: Ian Alberts; George Prenosil; Clemens Mingels; Karl Peter Bohn; Marco Viscione; Hasan Sari; Axel Rominger; Ali Afshar-Oromieh Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-21 Impact factor: 9.236
Authors: Dimitrios S Strauss; C Sachpekidis; K Kopka; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-10 Impact factor: 9.236